FY2027 EPS Estimates for Immunocore Reduced by HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Research analysts at HC Wainwright lowered their FY2027 earnings per share estimates for shares of Immunocore in a research note issued to investors on Friday, November 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $0.93 for the year, down from their previous estimate of $1.12. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunocore’s FY2028 earnings at $4.10 EPS and FY2029 earnings at $7.55 EPS.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.32. The firm had revenue of $135.80 million for the quarter, compared to analysts’ expectations of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The company’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.17 EPS.

Several other research analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Wednesday, October 8th. Zacks Research lowered Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 4th. Wells Fargo & Company started coverage on Immunocore in a research report on Friday, October 31st. They set an “overweight” rating and a $60.00 target price for the company. Jefferies Financial Group began coverage on Immunocore in a report on Monday, August 25th. They set a “buy” rating and a $48.00 target price on the stock. Finally, Morgan Stanley boosted their price target on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research note on Monday. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.00.

Immunocore Price Performance

NASDAQ:IMCR opened at $35.20 on Monday. Immunocore has a 52 week low of $23.15 and a 52 week high of $39.33. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00. The firm’s 50-day simple moving average is $33.95 and its 200 day simple moving average is $33.27. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -61.75 and a beta of 0.78.

Insider Buying and Selling at Immunocore

In related news, insider David M. Berman sold 22,532 shares of Immunocore stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $35.67, for a total transaction of $803,716.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Immunocore

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in shares of Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after purchasing an additional 311 shares during the last quarter. Virtus Investment Advisers LLC lifted its holdings in shares of Immunocore by 5.3% during the second quarter. Virtus Investment Advisers LLC now owns 12,472 shares of the company’s stock worth $391,000 after purchasing an additional 625 shares during the period. Envestnet Asset Management Inc. increased its holdings in Immunocore by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 67,259 shares of the company’s stock valued at $1,996,000 after purchasing an additional 735 shares during the period. Orion Porfolio Solutions LLC raised its position in Immunocore by 4.5% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock worth $752,000 after purchasing an additional 1,031 shares during the last quarter. Finally, Assetmark Inc. lifted its holdings in Immunocore by 3.7% during the 2nd quarter. Assetmark Inc. now owns 34,958 shares of the company’s stock worth $1,097,000 after buying an additional 1,248 shares during the period. 84.50% of the stock is currently owned by institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.